Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company

Core Viewpoint - Inspira Technologies Oxy B.H.N. Ltd. has announced a private placement offering to raise capital for working capital and general corporate purposes, with the closing expected around December 30, 2024 [1][4]. Company Overview - Inspira Technologies is a pioneering company in respiratory support technology, focusing on life-support innovations [4]. - The company has developed the Augmented Respiration Technology (INSPIRA™ ART), which aims to transform the $19 billion mechanical ventilation market by providing an alternative for patients with acute respiratory failure [8]. - The INSPIRA ART can stabilize decreasing oxygen saturation levels within minutes without the use of traditional ventilators, allowing patients to remain awake during treatment [8]. Product Development - The INSPIRA™ ART100 system has received FDA 510(k) clearance for use in Cardiopulmonary Bypass procedures and has also obtained Israeli AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures [9]. - Other products in development include the INSPIRA™ ART500, the INSPIRA™ Cardi-ART portable device, the VORTX orbiting Oxygen Delivery System, and the HYLA™ blood sensor, which are not yet tested or approved for human use [10]. Financial Details - The private placement consists of 4,608,715 ordinary shares and warrants at a combined purchase price of $0.70, with warrants having an exercise price of $1.10 per share and a term of eighteen months [4].